NCT07158086Recruiting
Molecular Underpinnings of Heart Failure, Integrative Multi-Omics, and Non-Coding RNA Profiling
Molecular Underpinnings of Heart Failure, Integrative Multi-Omics, and Non-Coding RNA Profiling: the BIOCARDIUM-HF Study
Source: ClinicalTrials.gov · Last updated 25 Sept 2026
Brief summary (registry, in English)
The main objective of the study is to achieve a comprehensive phenotyping of patients with heart failure, combining detailed clinical characterization with in-depth molecular profiling. By integrating clinical data with cutting-edge multi-omics techniques (including transcriptomics, epigenomics, and proteomics), this research aims to identify molecular signatures, particularly non-coding RNAs (ncRNAs), that are linked to the onset and progression of HF. Through advanced molecular profiling of biological samples and the analysis of clinical parameters, including advanced imaging, hemodynamic profiling, and biomarker analysis, the study will contribute to the deep phenotyping of HF patients. The secondary objective aims to uncover potential biomarkers that may serve as predictive indicators of disease progression and identify novel therapeutic targets, offering promising avenues for future treatments in this challenging patient population.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 500 (estimated)
- First submitted
- 27 Aug 2025
- Start date
- 1 Feb 2025
- Primary completion date
- 30 Nov 2030
- Lead sponsor
- University of Zurich
- Diseases
- Heart failure
- NCT number
- NCT07158086
What you commit to
- Study type: Observational
- Planned participants: 500
- From 1 Feb 2025 to the primary completion date, 30 Nov 2030
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients will be excluded if they meet any of the following conditions:
- Active malignancy or history of cancer with ongoing treatment (e.g., chemotherapy, radiotherapy, immunotherapy).
- Autoimmune or systemic inflammatory diseases.
Lab values
- Concomitant infections, including acute systemic infections (e.g., sepsis, pneumonia) or chronic infections with systemic impact (e.g., HIV, hepatitis B/C with elevated transaminases).
- Other exclusion criteria:
Age
- Age\<18 years old
Other
- Inability to provide written informed consent
Who the study is looking for
- Female and Male, age ≥18 years at screening.
- Diagnosis of Heart Failure according to ESC Heart Failure Guidelines
- Ability to understand the requirements of the study and to provide informed consent.
- Willingness to undergo follow-up.
Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University Hospital of Zurich Coordinator of this site? Confirm its status | Zurich | Switzerland | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.